Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plaque-associated oral bacteria refer to the complex, multi-species microbial community that resides within a structured biofilm on the surfaces of teeth and gums (NIH, 2017). This biofilm, commonly known as dental plaque, consists of hundreds of bacterial species—including Streptococcus mutans, Porphyromonas gingivalis, and Fusobacterium nucleatum—embedded in a self-produced extracellular matrix of polymers (Pocket Dentistry, 2016; Dimensions of Dental Hygiene, 2024). In a healthy oral environment, these bacteria exist in a state of homeostasis, providing protection against exogenous pathogens; however, environmental shifts such as frequent sugar consumption can lead to dysbiosis (NIH, 2004). This imbalance promotes the growth of acidogenic and inflammatory species, which are the primary etiological agents for dental caries and periodontal diseases (MouthHealthy, 2024; Allied Academies, 2023). Therapeutic interventions aim to control these populations through mechanical removal, antimicrobial rinses that disrupt bacterial membranes, and metabolic inhibitors like fluoride (NIH, 2021; UPenn, 2015). Furthermore, these bacteria are increasingly recognized for their role in systemic health, as their entry into the bloodstream can contribute to chronic inflammatory conditions such as cardiovascular disease and diabetes (Wichita Periodontists, 2025; NIH, 2021).
Drugs targeting plaque-associated oral bacteria work through several mechanisms: chlorhexidine and cetylpyridinium chloride disrupt bacterial cell membranes; fluoride and zinc ions inhibit glycolytic enzymes like enolase to reduce acid production; and antibiotics like amoxicillin or metronidazole inhibit cell wall synthesis or DNA function in specific pathogens (NIH, 2021; NIH, 2025). Additionally, novel strategies involve quorum quenching to disrupt biofilm organization and anti-adhesive agents to prevent initial bacterial attachment to the salivary pellicle (NIH, 2021; ResearchGate, 2024).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plaque-associated oral bacteria.